
Thursday, April 08, 2021 5:28:53 PM

Liked By
Spread the love. Be the first to like this post!
Recent CMMB News
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/11/2023 09:02:47 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/05/2023 09:50:08 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/05/2023 09:02:30 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/03/2023 12:06:21 PM
- Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients • PR Newswire (US) • 01/03/2023 12:00:00 PM
- Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis • PR Newswire (US) • 12/21/2022 12:00:00 PM
- Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy • PR Newswire (US) • 11/30/2022 12:00:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 11/18/2022 12:54:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 11/17/2022 09:57:27 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/16/2022 12:21:40 PM
- Initial Statement of Beneficial Ownership (3) • Edgar (US Regulatory) • 11/15/2022 09:04:26 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/14/2022 09:11:05 PM
- Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update • PR Newswire (US) • 11/11/2022 11:00:00 AM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/10/2022 09:13:07 PM
- Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19 • PR Newswire (US) • 11/09/2022 01:00:00 PM
- Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update • PR Newswire (US) • 11/01/2022 11:00:00 AM
- Chemomab Therapeutics to Present at Upcoming Scientific Conferences • PR Newswire (US) • 10/28/2022 11:00:00 AM
- Securities Registration: Employee Benefit Plan (s-8) • Edgar (US Regulatory) • 08/15/2022 08:07:34 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 08/12/2022 11:08:54 AM
- Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities • PR Newswire (US) • 08/12/2022 10:00:00 AM
- Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/12/2022 10:00:00 AM
- Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update • PR Newswire (US) • 08/01/2022 11:00:00 AM
- Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis • PR Newswire (US) • 06/27/2022 12:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 06/21/2022 11:01:09 AM
- Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors • PR Newswire (US) • 06/21/2022 11:00:00 AM
TNRG Files A Reg A Offering, To Raise $75 million • TNRG • Feb 1, 2023 10:07 AM
IQST - iQSTEL Announces Board Election and CPA Ratification Following Annual Shareholder Meeting • IQST • Feb 1, 2023 10:04 AM
1606 Corp. (OTC | CBDW) to Produce a New Inventory of CBD Smokables to Supply an Additional 2500 Retail Outlets, Engages Direct Marketing Expert to Head Efforts • CBDW • Feb 1, 2023 8:30 AM
ITRONICS RECEIVES VALUATION REPORT FOR ITS INTELLECTUAL PROPERTY TO OBTAIN NON-DILUTIVE FINANCING • ITRO • Feb 1, 2023 6:30 AM
Kona Gold Beverage, Inc Announces Distribution Agreement with Norman Distribution in Illinois • KGKG • Jan 31, 2023 9:00 AM
PSYC Provides Shareholders with Key Corporate Updates and Highlights Objectives for 2023 • PSYC • Jan 31, 2023 8:30 AM